Pfizer's CEO gains support of ex-execs amid activist investor talks
"We have decided not to be involved in the efforts of Starboard Value regarding Pfizer. We are fully supportive of Pfizer Chairman & CEO Albert Bourla, senior management and the board, and we are confident that over time they will deliver shareholder value," the two wrote, in a statement issued on behalf of them by Guggenheim Securities.
Wall Street Journal on MSN18h
Activist Accuses Pfizer of Pressuring Former ExecutivesThe fight between Starboard Value and drug giant Pfizer PFE-2.82%decrease; red down pointing triangle took an unusual, ...
As the battle over Pfizer’s future continues, former executives said they would no longer support activist investor Starboard ...
Leerink Partners analyst David Risinger has maintained their neutral stance on PFE stock, giving a Hold rating on October 7. David ...
Pfizer’s situation with activist investor Starboard Value is already getting messy. | After initially supporting a meeting ...
Looking at a slightly longer term, the performance of PFE stock with respect to the index has been quite volatile in recent ...
Summit County's Department of Health announced clinics in Akron are now offering the new Pfizer COVID-19 vaccine.
In prostate cancer, Pfizer’s Talzenna already holds the broadest FDA approval within the PARP inhibitor class. | In prostate ...
Pfizer said on Thursday a combination of its drugs, Talzenna and Xtandi, helped prolong the lives of patients with a type of ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback